ROE

Tangerine’s socially responsible funds nabbed three prestigious FundGrade A+® Awards, showing investors can align their portfolio with their values without sacrificing performance.

A new bond issue strengthens Agilyx's finances, funding a dual strategy focused on immediate earnings and long-term tech licensing in plastic recycling.

With its Q4 results announcement imminent, specialty insurer Trisura is under scrutiny to prove it can sustain growth amid market pressures and investor concerns.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

A new report reveals a grim reality: the typical American worker has under $1,000 for retirement. Is the system, not the saver, fundamentally broken?

New data reveals Orca-T cell therapy boosts survival and cuts complications in blood cancer, as the company prepares for a potential FDA approval this year.

A new report reveals a looming crisis: rising healthcare costs will consume more than 100% of Social Security benefits for future generations of retirees.

IUOE Local 150 backs Speaker Welch for State Central Committeeperson, signaling a major power play in Illinois Democratic politics post-Danny Davis.

With 46% of developers distrusting AI code, Qodo 2.0's new multi-agent architecture aims to restore faith by delivering more accurate, context-aware reviews.

The frozen potato giant appoints an AB InBev veteran as Executive Chair and a new CFO, signaling a major push for global expansion and shareholder value.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Nasdaq-listed Zeta Network Group is exploring real-world asset tokenization, signaling a pivotal move beyond Bitcoin for institutional treasury management.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

VENU closes a $13M deal for its first indoor venue, bringing an innovative fractional ownership "FireSuite" concept to the Denver area.

A landmark survey reveals a massive capital rotation as 96% of institutions chase AI and 81% move to private markets to navigate a fragmenting world.